Licensed vaccine
ProQuad
FDA-licensed vaccine · Merck Sharpe & Dohme LLC · STN 125108
Key facts
| Trade name | ProQuad |
|---|---|
| Proper name | Measles, Mumps, Rubella and Varicella Virus Vaccine Live |
| Manufacturer | Merck Sharpe & Dohme LLC |
| Submission tracking number (STN) | 125108 |
| FDA product areas | Biologics |
| Recent FDA documents | November 5, 2024 Approval Letter - ProQuad, August 21, 2023 Approval Letter - ProQuad, February 27, 2023 Statistical Review - ProQuad, February 27, 2023 Clinical Review - ProQuad, February 27, 2023 Approval Letter - ProQuad, April 13, 2021 Approval Letter - ProQuad, Package Insert - Frozen Formulation - ProQuad, Patient Information (Frozen) - ProQuad, Patient Information (Refrigerated) - ProQuad, September 15, 2020 Approval Letter - PROQUAD, January 22, 2019 Approval Letter - PROQUAD, Package Insert - Frozen Formulation - Recombinant Human Albumin (RHA) - ProQuad |
| FDA page updated | Nov 6, 2024 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 10–99 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: